Current antiretroviral therapies preserve the immune system, reduce HIV-associated morbidity and prevent HIV transmission but still, the virus persistence in CD4 cells remains a crucial factor to battle. Previous studies have explored the role of interleukin-2-inducible tyrosine kinase (ITK) inhibition in lymphoma, allergy and other infectious diseases.